146803-41-0

Usage

Uses

Used in Pharmaceutical Industry:
FMOC-ALA-ALDEHYDE is used as an intermediate in the synthesis of α-amino aldehydes and peptide aldehydes for the development of new drugs and therapeutic agents. Its role in the synthesis process is essential, as it allows for the creation of a wide range of bioactive molecules with potential applications in treating various diseases and medical conditions.
Used in Organic Chemistry Research:
In the field of organic chemistry, FMOC-ALA-ALDEHYDE is used as a building block for the synthesis of complex organic molecules. Its unique structure and reactivity make it a valuable tool for researchers working on the development of new compounds with specific properties and functions.
Used in Chemical Synthesis:
FMOC-ALA-ALDEHYDE is also employed in chemical synthesis processes, where it serves as a key component in the production of various chemical products. Its ability to react with other compounds and form new structures makes it an indispensable resource in the chemical industry.

Upstream product

• 125814-20-2 Fmoc-L-Ala-NCA 
• 103321-50-2 9H-fluoren-9-ylmethyl [(1S)-2-chloro-1-methyl-oxoethyl]carbamate 
• 161529-13-1 (S)-2-(N-fluorenylmethoxycarbonylamino)propanol 
• 35661-39-3 N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine 
• 146346-88-5 methyl 2-(((9H-fluoren-9-yl)methoxy)carbonyl)aminopropanoate 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 198542-03-9 (9H-fluoren-9-yl)methyl (S)-(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 

Downstream Products

• 276888-31-4 2-[2-(5-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-pentanoyloxy)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-butyrylamino]-4-methyl-pentanoic acid methyl ester 
• 373605-00-6 2-[2-(5-benzyloxycarbonylamino-2-tert-butoxycarbonylamino-pentanoyloxy)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-butyrylamino]-4-methyl-pentanoic acid benzyl ester 
• 762232-44-0 benzyl N-(2-Fmoc-amino-L-methylethyl)glycinate 
• 382149-37-3 {[2-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid benzyl ester 
• 382149-22-6 {[2-(2-{[2-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetylamino)-propyl]-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid benzyl ester 
• 948888-01-5 4(S)-[(9-fluorenylmethoxycarbonyl)amino]-2-pentenoic acid benzyl ester 
• 1311399-87-7 FmocNH-L-Ala-ψ[C3H3NO]-CO-NH Phe-COOMe 
• 1447194-67-3 benzyl (4S)-4-(N-fmoc)-amino-3-oxopentanoate 

Relevant academic research and scientific papers

α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions

The use of peptidomimetic scaffolds is a promising strategy for the inhibition of protein-protein interactions (PPIs). Herein, we demonstrate that sulfono-γ-AApeptides can be rationally designed to mimic the p53 α-helix and inhibit p53-MDM2 PPIs. The best

Rapid synthesis of internal peptidyl α-ketoamides by on resin oxidation for the construction of rhomboid protease inhibitors

Rhomboid proteases are intramembrane serine proteases, which are involved in a wide variety of biological processes and have been implied in various human diseases. Recently, peptidyl α-ketoamides have been reported as rhomboid inhibitors with high potency and selectivity-owing to their interaction with both the primed and non-primed site of the target protease. However, their synthesis has been performed by solution phase chemistry. Here, we report a solid phase strategy towards ketoamides as rhomboid protease inhibitors, allowing rapid synthesis and optimization. We found that the primed site binding part of inhibitors is crucial for potency.

Solid-phase synthesis of peptide vinyl sulfones as potential inhibitors and activity-based probes of cysteine proteases

(Matrix presented) Peptide vinyl sulfones were prepared from 2-chlorotrityl resin-bound phenolic amino vinyl sulfones in high yield and purity. This method enables the convenient synthesis of peptide vinyl sulfones having different amino acids at the Psu

Helical Sulfono-γ-AApeptides with Aggregation-Induced Emission and Circularly Polarized Luminescence

Aggregation-induced emission (AIE) was intensively studied because of packing of small molecules and polymers; however, mid-molecular-weight (1000-3000) molecular scaffold containing a precise number of AIE luminogens is rare. Herein, we report the investigation of three tetraphenylethylene (TPE)-modified sulfono-γ-AApeptides in which multiple TPE moieties are conjugated to the chiral right-handed helical peptidomimetic backbone as functional side chains. The crystal structure of the TPE-α/sulfono-γ-AA peptide 1 demonstrates that because of the rigid helical scaffold of the TPE-α/sulfono-γ-AA peptides, the intramolecular rotations of the TPE with short linker are restricted, therefore leading to the boosted fluorescent emission in solution. Peptides 2 and 3 exhibit aggregation-induced emission enhancement (AIEE), possibly because of the combination of both AIE and rotation restriction. Moreover, because of their preoriented assembly induced by the right-handed helical scaffold, these emissive chiral luminogens show effective circularly polarized luminescence signals with high dissymmetry factor glum. Finally, the amphiphilic nature of TPE-α/sulfono-γ-AA peptides could enable them to penetrate the bacterial membranes and exhibit strong fluorescence. Their antimicrobial activity and labeling-free character could further augment their potential applications in both materials and biomedical sciences.

Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor

Angiogenesis, formation of new blood vessels from the existing vascular network, is a hallmark of cancer cells that leads to tumor vascular proliferation and metastasis. This process is mediated through the binding interaction of VEGF-A with VEGF receptor

Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions

Peptidomimetics have gained great attention for their function as protein-protein interaction (PPI) inhibitors. Herein, we report the design and investigation of a series of right-handed helical heterogeneous 1:1 α/Sulfono-I-AA peptides as unprecedented inhibitors for p53-MDM2 and p53-MDMX. The most potent helical heterogeneous 1:1 α/Sulfono-I-AA peptides were shown to bind tightly to MDM2 and MDMX, with Kd of 19.3 and 66.8 nM, respectively. Circular dichroism spectra, 2D-NMR spectroscopy, and the computational simulations suggested that these helical sulfono-I-AA peptides could mimic the critical side chains of p53 and disrupt p53/MDM2 PPI effectively. It was noted that these 1:1 α/Sulfono-I-AA peptides were completely resistant to proteolytic degradation, boosting their potential for biomedical applications. Furthermore, effective cellular activity is achieved by the stapled 1:1 α/Sulfono-I-AA peptides, evidenced by significantly enhanced p53 transcriptional activity and much more induced level of MDM2 and p21. The 1:1 α/Sulfono-I-AA peptides could be an alternative strategy to antagonize a myriad of PPIs.

Β?CATENIN/ B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION INHIBITING PEPTIDOMIMETICS

Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β?catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β?catenin and disrupt β?catenin/BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.

PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS

Provided herein are phosphor(n)amidatacetal and phosph(on)atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver.

COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY

This application pertains to orthogonally protected esters of peptide nucleic acid (PNA) monomers, which ester groups can be removed under conditions that permit typical backbone and side chain acid- and base-labile protecting groups to remain substantially intact thereby permitting the high yield of PNA monomer carboxylic acids that are suitable for use in PNA oligomer synthesis. Exemplary ester groups include, but are not limited to, 2,2,2-trichloroethyl (TCE), 2,2,2-tribromoethyl (TBE), 2-bromoethyl (2-BE) and 2-iodoethyl groups (2-IE). This invention also pertains to novel methods for the synthesis of Backbone Ester compounds and related Backbone Ester Acid Salts.